Close
FINDING CURES TOGETHER<sup>SM</sup>

The AACR Announces AACR-Johnson & Johnson Lung Cancer Innovation Science Grants

Grant applications are due May 2
2/1/2018

​PHILADELPHIA — The American Asso​ciation for Cancer Research (AACR) is extremely proud to announce the launch of the AACR-Johnson & Johnson Lung Cancer Innovation Science Grants to stimulate research aimed at eradicating this devastating disease. This exciting new funding opportunity, which is supported by the Johnson & Johnson Lung Cancer Initiative, will ignite scientific innovation and transformational advances against lung cancer.

A total of $4.5 million will be made available in research funding in support of meritorious research projects. Three multi-institutional research teams that seek novel approaches to the prevention, interception, and cure of lung cancer will each be awarded up to $1.5 million over a period of three years. The deadline for submission is Wednesday, May 2, at 1 p.m. Eastern Standard Time. Research projects will begin on July 1, 2018.

“Lung cancer is the leading cause of cancer death worldwide, and more research is urgently needed if we are to markedly reduce incidence and mortality from this complex disease. These grants will identify innovative strategies to eliminate behaviors that increase lung cancer risk, devise new ways to intercept a lung cancer-causing process before lung cancer occurs, and develop effective treatments that offer the potential for a cure,” said Margaret Foti, PhD, MD (hc), chief executive officer of the AACR.

Proposals submitted for this important funding opportunity should consider the concepts that lung cancer is often caused by behaviors that lead to: chronic exposure to respiratory carcinogens that produce cellular/genomic damage; chronic inflammation; alterations in innate and adaptive immunity; and changes in the pulmonary microbiome. Consequently, these events may trigger the escape of transformed cells from immune surveillance. Proposals that characterize premalignant lesions or that substantially improve the detection of lung cancer at more curable stages will also be prioritized for funding.

Grant applications will be accepted from multi-institutional teams, composed of principal investigators from at least two, but no more than three, different institutions. Recipients will be notified by June.

Applications must be submitted by 1 p.m. Eastern Standard Time, May 2, 2018, using the proposalCENTRAL website. Further details are available online. Additional inquiries may be directed to the AACR’s Scientific Review and Grants Administration department, at grants@aacr.org.